Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

878 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Upadacitinib in patients with psoriatic arthritis and an inadequate response to non-biological therapy: 56-week data from the phase 3 SELECT-PsA 1 study.
McInnes IB, Kato K, Magrey M, Merola JF, Kishimoto M, Pacheco-Tena C, Haaland D, Chen L, Duan Y, Zueger P, Liu J, Lippe R, Pangan AL, Behrens F. McInnes IB, et al. Among authors: kishimoto m. RMD Open. 2021 Oct;7(3):e001838. doi: 10.1136/rmdopen-2021-001838. RMD Open. 2021. PMID: 34663636 Free PMC article. Clinical Trial.
Ixekizumab efficacy and safety with and without concomitant conventional disease-modifying antirheumatic drugs (cDMARDs) in biologic DMARD (bDMARD)-naïve patients with active psoriatic arthritis (PsA): results from SPIRIT-P1.
Coates LC, Kishimoto M, Gottlieb A, Shuler CL, Lin CY, Lee CH, Mease PJ. Coates LC, et al. Among authors: kishimoto m. RMD Open. 2017 Dec 22;3(2):e000567. doi: 10.1136/rmdopen-2017-000567. eCollection 2017. RMD Open. 2017. PMID: 29299340 Free PMC article.
Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial.
van der Heijde D, Cheng-Chung Wei J, Dougados M, Mease P, Deodhar A, Maksymowych WP, Van den Bosch F, Sieper J, Tomita T, Landewé R, Zhao F, Krishnan E, Adams DH, Pangallo B, Carlier H; COAST-V study group. van der Heijde D, et al. Lancet. 2018 Dec 8;392(10163):2441-2451. doi: 10.1016/S0140-6736(18)31946-9. Epub 2018 Oct 22. Lancet. 2018. PMID: 30360964 Clinical Trial.
Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebo-controlled, phase 2/3 trial.
van der Heijde D, Song IH, Pangan AL, Deodhar A, van den Bosch F, Maksymowych WP, Kim TH, Kishimoto M, Everding A, Sui Y, Wang X, Chu AD, Sieper J. van der Heijde D, et al. Among authors: kishimoto m. Lancet. 2019 Dec 7;394(10214):2108-2117. doi: 10.1016/S0140-6736(19)32534-6. Epub 2019 Nov 12. Lancet. 2019. PMID: 31732180 Clinical Trial.
Reactive arthritis after COVID-19 infection.
Ono K, Kishimoto M, Shimasaki T, Uchida H, Kurai D, Deshpande GA, Komagata Y, Kaname S. Ono K, et al. Among authors: kishimoto m. RMD Open. 2020 Aug;6(2):e001350. doi: 10.1136/rmdopen-2020-001350. RMD Open. 2020. PMID: 32763956 Free PMC article.
Prevalence and distribution of peripheral musculoskeletal manifestations in spondyloarthritis including psoriatic arthritis: results of the worldwide, cross-sectional ASAS-PerSpA study.
López-Medina C, Molto A, Sieper J, Duruöz T, Kiltz U, Elzorkany B, Hajjaj-Hassouni N, Burgos-Vargas R, Maldonado-Cocco J, Ziade N, Gavali M, Navarro-Compan V, Luo SF, Monti S, Tae-Jong K, Kishimoto M, Pimentel-Santos FM, Gu J, Schiotis R, van Gaalen FA, Geher P, Magrey M, Ibáñez Vodnizza SE, Bautista-Molano W, Maksymowych W, Machado PM, Landewé R, van der Heijde D, Dougados M. López-Medina C, et al. Among authors: kishimoto m. RMD Open. 2021 Jan;7(1):e001450. doi: 10.1136/rmdopen-2020-001450. RMD Open. 2021. PMID: 33462157 Free PMC article.
Pustular Psoriasis and Associated Musculoskeletal Disorders.
Callis Duffin K, Bachelez H, Mease PJ, Rosen C, Garg A, Zudak E, Elkayam O, Merola J, Chau J, Kishimoto M, Furer V, Helliwell PS. Callis Duffin K, et al. Among authors: kishimoto m. J Rheumatol. 2021 Mar 15:jrheum.201673. doi: 10.3899/jrheum.201673. Online ahead of print. J Rheumatol. 2021. PMID: 33722939
Clinical features of psoriatic arthritis.
Kishimoto M, Deshpande GA, Fukuoka K, Kawakami T, Ikegaya N, Kawashima S, Komagata Y, Kaname S. Kishimoto M, et al. Best Pract Res Clin Rheumatol. 2021 Jun;35(2):101670. doi: 10.1016/j.berh.2021.101670. Epub 2021 Mar 17. Best Pract Res Clin Rheumatol. 2021. PMID: 33744078 Review.
Trial of Upadacitinib and Adalimumab for Psoriatic Arthritis.
McInnes IB, Anderson JK, Magrey M, Merola JF, Liu Y, Kishimoto M, Jeka S, Pacheco-Tena C, Wang X, Chen L, Zueger P, Liu J, Pangan AL, Behrens F. McInnes IB, et al. Among authors: kishimoto m. N Engl J Med. 2021 Apr 1;384(13):1227-1239. doi: 10.1056/NEJMoa2022516. N Engl J Med. 2021. PMID: 33789011 Free article. Clinical Trial.
878 results